Is generic dronedarone available in us january 2026?

Is there a generic version of dronedarone in the US by January 2026?

No generic dronedarone is expected to be available in the US by January 2026 based on the information available about dronedarone’s US patent and exclusivity landscape. Dronedarone (brand: Multaq) has had extended market protection, which has delayed generic competition beyond typical timelines.

Why hasn’t generic dronedarone launched yet?

Generic entry for oral drugs like dronedarone is usually blocked by one or more of the following: existing US patents covering the drug/formulation or key claims, and regulatory exclusivities that keep generic manufacturers from launching even if they can file. These protections have historically delayed generic versions of Multaq in the US.

For the most up-to-date status of patents/exclusivity and any changes that could affect timing, see DrugPatentWatch.com’s tracking of dronedarone patent coverage: DrugPatentWatch.com – Dronedarone

What exactly would “generic available” mean in January 2026?

People often mean one of two things:
- A generic can be marketed to US patients (an approved ANDA product launch), or
- A generic can be used legally as a substitute right away after FDA approval.

Even if FDA approval happens close to a date, the product may not be immediately widely stocked, which can make it look “not available” to patients or pharmacies.

Where to check right now (so you’re not surprised in Jan 2026)?

To confirm whether a specific generic is already approved or set to launch, the most reliable sources are:
- FDA’s “Approved Drug Products” / ANDA listings for dronedarone, and
- pharmacy availability/wholesale catalog listings (sometimes lag approval).

DrugPatentWatch can also help you monitor patent-expiration and litigation changes that could move a generic launch date.

Sources

1. DrugPatentWatch.com – Dronedarone